New hope for Hard-to-Treat nasopharyngeal cancer: targeted drug HLX43 enters phase 2 trial
NCT ID NCT06839066
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests HLX43, a drug that targets a protein called PD-L1 on cancer cells and delivers a toxin to kill them. It is for people with recurrent or metastatic nasopharyngeal carcinoma who have failed or cannot tolerate second-line therapy. About 70 participants will receive one of three doses to find the best balance of safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HLX43 (an antibody-drug conjugate that targets PD-L1 and delivers a chemotherapy-like toxin to cancer cells)
What this could lead to
If successful, this could offer a new treatment option for people with advanced nasopharyngeal cancer who have run out of standard therapies.
What could go wrong
This is a small, early-phase trial (70 people) testing different doses, so it may not show strong enough benefit or could have unexpected side effects. The drug is still experimental.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA (NPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen
RECRUITINGShenzhen, Guangdong, China
-
Dongguan People's Hospital
RECRUITINGDongguan, Guangdong, China
-
First Affiliated Hospital of Gannan Medical University
RECRUITINGGanzhou, Jiangxi, China
-
Fujian Cancer Hospital
RECRUITINGFuzhou, Fujian, China
-
Guangxi Medical University Cancer Hospital
RECRUITINGNanning, Guangxi, China
-
Guizhou Medical University Cancer Hospital
RECRUITINGGuiyang, Guizhou, China
-
Sichuan Cancer Hospital
RECRUITINGChengdu, Sichuan, China
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
-
The First Affiliated Hospital of Guangdong Pharmaceutical University
RECRUITINGGuangzhou, Guangdong, China
-
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology
RECRUITINGWuhan, Hubei, China
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, China
-
Xiangya Hospital of Central South University
RECRUITINGChangsha, Hunan, China
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, China
-
Zhongshan City People's Hospital
RECRUITINGGuangzhou, Guangdong, China